Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascentage Pharma Group International - American Depository Shares (NQ:AAPG)

28.41 +0.66 (+2.38%)
Streaming Delayed Price Updated: 11:48 AM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ascentage Pharma Group International - American Depository Shares

Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.